Here is a data-driven look at Glaxosmithkline Pharmaceuticals Ltd. (GLAXO), covering financial performance, valuation, and shareholding trends.
Glaxo Pharma Revenue Trend
Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹3,895 Cr in FY2025, a 8.9% increase from ₹3,576 Cr in FY2024.
A 3.0% CAGR over 13 years is underwhelming. In real terms, Glaxosmithkline Pharmaceuticals Ltd.'s revenue has barely grown from ₹2,651 Cr to ₹3,895 Cr.
At ₹3,895 Cr in annual revenue, Glaxosmithkline Pharmaceuticals Ltd. is one of the mid-sized players in the pharmaceuticals space.
The consistency stands out: 5 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹3,895 Cr | +8.9% |
| FY2024 | ₹3,576 Cr | +8.1% |
| FY2021 | ₹3,309 Cr | +2.6% |
| FY2020 | ₹3,224 Cr | +3.1% |
| FY2019 | ₹3,128 Cr | — |
View Glaxosmithkline Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Glaxo Pharma Profitability
Year-over-year, net profit grew 57.2% from ₹590 Cr to ₹928 Cr in FY2025 for Glaxosmithkline Pharmaceuticals Ltd..
The company squeezed out better margins in FY2025, with net margin at 23.8% versus 16.5% in FY2024.
At ₹54.76 per share (diluted), FY2025 earnings were up year-over-year from ₹34.83.
Is Glaxo Pharma Undervalued
The P/E Ratio valuation pegs Glaxosmithkline Pharmaceuticals Ltd.'s fair value at ₹3,693, which is 69.3% upside from the current price.
Glaxosmithkline Pharmaceuticals Ltd. shares are currently trading at ₹2,181.00.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹3,693 | 69.3% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Glaxosmithkline Pharmaceuticals Ltd. with detailed assumptions →
Glaxo Pharma Shareholding Pattern
Promoters continue to hold 75.0% of the company, unchanged over recent quarters.
Foreign institutional investors (FIIs) held 4.6% as of March 2026, down from 4.9% a year ago.
Domestic institutional investors (DIIs) held 7.7% as of March 2026, down from 7.7% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 75.0% | 4.6% | 7.7% | 12.7% |
| Dec 2025 | 75.0% | 4.6% | 7.7% | 12.7% |
| Sep 2025 | 75.0% | 4.8% | 7.8% | 12.4% |
| Jun 2025 | 75.0% | 4.9% | 7.7% | 12.4% |
Track quarterly shareholding changes for Glaxosmithkline Pharmaceuticals Ltd. →
Glaxo Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹41.08B (up 15.5% YoY from ₹35.57B).
Top categories: Cash & ST Investments (40.3%), Other Assets (33.8%), Inventories (11.7%).
Of the ₹41.08B in liabilities and equity, 47.5% is shareholder equity, 0.2% is interest-bearing debt, and 52.3% is operating liabilities. Over the year, debt is down 46.7% and equity is up 9.8%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 16.57B |
| Receivables | 2.93B |
| Inventories | 4.82B |
| Property, Plant & Equipment | 2.75B |
| Intangibles & Goodwill | 133.32M |
| Other Assets | 13.89B |
| Category | Value |
|---|---|
| Equity | 19.51B |
| Short-term Debt | 74.59M |
| Long-term Debt | 24.92M |
| Trade Payables | 7.08B |
| Other Liabilities | 14.39B |
What Stands Out About Glaxo Pharma
Bringing the key threads together for Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) as a pharmaceuticals investment opportunity.
Revenue of ₹3,895 Cr in FY2025, up 8.9% year-over-year.
Long-term revenue has been compounding at 3.0% annually over 13 years.
The company is profitable, with a net margin of 23.8% and net income of ₹928 Cr.
The P/E Ratio model implies 69.3% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Glaxosmithkline Pharmaceuticals Ltd..